The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ARGENX SE | SPONSORED ADR | 04016X101 | 6,358,445 | 16,315 | SH | SOLE | 16,315 | 0 | 0 | |||
| ARROWHEAD PHARMACEUTICALS IN | COM | 04280A100 | 30,613,183 | 858,474 | SH | SOLE | 858,474 | 0 | 0 | |||
| ARVINAS INC | COM | 04335A105 | 15,486,216 | 623,941 | SH | SOLE | 623,941 | 0 | 0 | |||
| BLUEPRINT MEDICINES CORP | COM | 09627Y109 | 28,375,978 | 448,987 | SH | SOLE | 448,987 | 0 | 0 | |||
| C4 THERAPEUTICS INC | COM STK | 12529R107 | 2,091,807 | 760,657 | SH | SOLE | 760,657 | 0 | 0 | |||
| GENMAB A/S | SPONSORED ADS | 372303206 | 6,638,370 | 174,648 | SH | SOLE | 174,648 | 0 | 0 | |||
| ISHARES RUSSELL 2000 ETF TR | UNIT | 464287655 | 28,090,500 | 150,000 | SH | Put | SOLE | 0 | 0 | 150,000 | ||
| KYMERA THERAPEUTICS INC | COM | 501575104 | 14,973,962 | 651,325 | SH | SOLE | 651,325 | 0 | 0 | |||
| MERUS N V | COM | N5749R100 | 20,408,620 | 775,109 | SH | SOLE | 775,109 | 0 | 0 | |||
| OLEMA PHARMACEUTICALS INC | COM | 68062P106 | 2,257,500 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | |||
| PIERIS PHARMACEUTICALS INC | COM | 720795103 | 546,678 | 3,303,190 | SH | SOLE | 3,303,190 | 0 | 0 | |||
| REGENXBIO INC | COM | 75901B107 | 17,393,579 | 870,114 | SH | SOLE | 870,114 | 0 | 0 | |||
| SILENCE THERAPEUTICS PLC | ADS | 82686Q101 | 7,217,282 | 1,312,233 | SH | SOLE | 1,312,233 | 0 | 0 | |||